New market - 1 trader so far.
Early - only 1 trader so far. Be one of them.
YES if
The FDA grants approval for retatrutide (Eli Lilly's triple agonist) for a weight-loss or obesity indication, as confirmed by an official FDA approval letter or Eli Lilly press release, by December 31, 2027.
Resolves by Dec 29, 2027.
Suggested by Hero Market from marketwatch.com: "A new wave of weight-loss therapies aims to be better than today’s GLP-1s"